This multidisciplinary PPP focuses on the reduction of the SARS-CoV-2 transmission risk for athletes and spectators in semi-indoor and indoor sports venues, with emphasis on football stadiums, indoor halls and fitness centers. Crowd control, air cleaning and face masks are considered, either separately or combined, in five practical case studies.
Hubrecht Organoid Technology and GlaxoSmithKline will together develop a human relevant Lung and Colon Immuno-Oncology model using Tumor Organoids, to better predict drug effectiveness for small molecule therapies.
Atherosclerosis is the main underlying cause of cardiovascular disease (CVD) and due to its multifactorial natural is often studied in animal models. Here the aim is to develop an innovative ex vivo system to study the atherosclerotic disease process based on the actual human atherosclerotic plaque. In line with the Transition to Animal-free Innovation (TPI), the aim is to develop a model that generates data on the effect of novel drugs that is highly translatable to the effect of the novel drug in the cardiovascular patient, while at the same time minimising the number of laboratory animals used. Moreover, the aim is to utilise this model to discover new biomarkers of successful treatment, which could expedite the transition of CVD therapeutic into clinical trial.
The knowledge is missing that is essential for cost-effective roll-out of personalised treatment of insomnia. This project solves the bottleneck by creating a research platform for combined online behavioural change intervention and long-term monitoring of sleep, traits and health. A growing database will allow for optimised sleep interventions tailor to personalised needs, capacities, limitations and estimated benefits.
This project aims to unravel mechanisms underlying beneficial effects of a novel food supplement on cognitive performance. This may contribute to the prevention of cognitive impairment and ultimately dementia. Focus will be on adults with an emerging pre-mild cognitive impairment condition who will benefit most from evidence-based intervention and prevention strategies.
The aim is to improve vaccines by including viral innate immune antagonists that are co-expressed with the antigen to boost vaccine efficacy.
Ex-COVID-19 patients will undergo medical tests and biological samples will be analysed to increase the understanding of who is at risk for chronic disease. The influence of environmental factors and of a lifestyle intervention will be analysed, and lab research will contribute to better mechanistic insights providing leads for interventions.
The human pluripotent stem cell derived heart models will be used for a rapid evaluation of important COVID-19 therapies and develop SARS-COV-2 disease models to investigate how infection affects the heart. Impact beyond conventional approaches will be accelerated by providing data immediately relevant to clinicians, within months of the project start.
Addition of glycerol esters of short chain fatty acid (eSCFA) to pig feed has beneficial health effects and can thereby reduce the use of antibiotics in the farming industry. This project investigates which specific antimicrobial peptides are upregulated by eSCFA and determines how these peptides add to the health benefit.
Angiotensin-II is a protein that plays a role in the development of acute lung injury in patients suffering from COVID-19 infection. Valsartan is a well-known, cheap drug in cardiovascular medicine with little side effects that blocks Angiotensin-II. This project investigates whether valsartan can prevent acute lung injury in COVID-19 infection.